SCHEMBL26506586

SCHEMBL26506586

COC(=O)c1ccccc1Oc1nc(Nc2ccc(C(N)=O)cc2)ncc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 3/20 0.56
▸ PRKAA2 P54646 1/20 0.56
▸ PRKAA1 Q13131 1/20 0.56
▸ ULK2 Q8IYT8 1/20 0.56
▸ AURKA O14965 5/20 0.47
▸ JAK2 O60674 3/20 0.47
▸ AURKB Q96GD4 2/20 0.47
▸ GSK3B P49841 2/20 0.46
▸ MAPK8 P45983 3/20 0.45
▸ MAPK9 P45984 2/20 0.45
▸ CHEK1 O14757 1/20 0.44
▸ NTRK2 Q16620 1/20 0.44
▸ IKBKB O14920 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SIRT2 Q8IXJ6 1/20 0.44
▸ MAPK10 P53779 2/20 0.43
▸ EGFR P00533 1/20 0.43
▸ IGF1R P08069 1/20 0.42
▸ CDC7 O00311 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26506589 0.93 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2AURKA
SCHEMBL26506580 0.90 ULK1 (0.58) ULK1PRKAA2PRKAA1ULK2AURKA
SCHEMBL26506554 0.89 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2MAPK8
SCHEMBL26506579 0.89 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2AURKA
SCHEMBL26506551 0.88 ULK1 (0.61) ULK1PRKAA2PRKAA1ULK2MAPK9
SCHEMBL26506572 0.86 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2AURKA
SCHEMBL26506558 0.86 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2AURKA
SCHEMBL26506581 0.86 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2AURKA
SCHEMBL26506548 0.86 ULK1 (0.67) ULK1PRKAA2PRKAA1ULK2MAPK8
SCHEMBL26506588 0.85 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME ULK2, ULK1, ULK3 ULK1 2/4885PRKAA2 130/4885PRKAA1 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback